VCYT News and Press, Veracyte Inc. From 10/12/23

Two studies highlight the value of adding Envisia results to standard-of-care procedures for identifying patients at increased risk of progressive disease Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annua...

Findings presented at the 2023 ASTRO Annual Meeting expand substantial body of evidence demonstrating Decipher Prostate test’s ability to help inform prostate cancer treatment decisions. Additional study suggests level of evidence supporting commercially available genomic classifie...

Company also introduces research-use-only Afirma Genomic Resource for Intelligent Discovery (GRID) platform for additional insights into thyroid nodules and cancer Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) A...

Veracyte, Inc . (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Ann...

2023-09-27 09:14:49 ET More on Veracyte Veracyte: Testing Numbers Stretching Higher But Valuations Uncertain Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracyte For further details see: Veracyte names Phillip Febbo as chi...

Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte’s global team of research and development, medi...

- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles - Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC)...

Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as si...

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced t...

2023-09-02 06:15:00 ET The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing. In the past five years, the genetic diagnostics company Veracyte (NASDAQ: VCYT) has produced cumulati...